Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 88

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 88
---
expense), net10,265 (25,974)(46,722)(Loss) income before income taxes(63,106)61,701 13,302 Income tax (expense) benefit(36,454)(19,746)2,607 Net (loss) income$(99,560)$41,955 $15,909 (1) During the year ended December 31, 2024, the remaining other operating expenses relates to restructuring charges, a loss on lease termination and acquisition-related charges. During the years ended December 31, 2023 and 2022, the remaining other operating expenses relates to step-up of acquired Flexion fixed assets and inventory to fair value and acquisition-related charges.The Company’s long-lived assets are primarily located in the U.S. For information on the Company’s fixed assets located outside of the U.S., refer to Note 6, Fixed Assets.

NOTE 21—SUBSEQUENT EVENTS (UNAUDITED)

Acquisition of GQ Bio Therapeutics GmbHAs of December 31, 2024, the Company owned approximately 19% of GQ Bio. On February 25, 2025, Pacira Therapeutics, Inc., a wholly-owned subsidiary of the Company, entered into a securities purchase agreement to acquire the remaining 81% of GQ Bio for approximately $32 million, net of working capital and other transaction adjustments. The net purchase price includes $8 million to be paid over three years pursuant to a key employee holdback agreement and a post-closing indemnity holdback of $6 million, whereas the remaining $18 million was paid at closing using cash on hand.Brisbane, California Office LeaseIn February 2025, the Company signed a lease for an office in Brisbane, California to be used for selling, general and administrative purposes. As a result, the Company recorded $0.5 million of right-of-use assets in exchange for lease obligations in the first quarter of 2025.

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-48